The double-blind, randomized, placebo-controlled trial enrolled 60 patients with non-constipation FBD.
The double-blind, randomized, placebo-controlled trial enrolled 60 patients with non-constipation FBD. The treatment group received the probiotic combination twice daily. Both the treatment and placebo groups were evaluated four times at a clinic and then four weeks later after the treatment period was over.
The endpoints were subjective. The primary endpoints were global relief of gastrointestinal (GI) symptoms, assessed by a score on a 7-point scale, from “substantially worse” to “substantially improved,” and satisfaction with treatment, evaluated via survey. Secondary endpoints included change in severity of functional GI symptoms, including abdominal bloating, well being, and quality of life.
At evaluation at four and eight weeks, the probiotic group showed less-severe bloating symptoms compared to the placebo group-up to a 15% reduction in bloating, the researchers said.
“L-NCFM and B-LBi07 twice a day improve symptoms of bloating in patients with FBDs. These data supports the role of intestinal bacteria in the pathophysiology of FBD and the role for probiotic bacteria in the management of these disorders,” the researchers stated.
Recent study compares the effectiveness of two probiotic products on colicky infants
October 31st 2024The study compared AB-Biotics and Kaneka Probiotics’ probiotic formulation of Bifidobacterium longum KABP®-042 and Pediococcus pentosaceus KABP®-041 to Lactobacillus reuteri DSM17938 (LR) from Biogaia.
New review paper highlights gut-brain benefits of novel herbal blend, Digexin
September 16th 2024NXT USA has announced the publication of a narrative review that offers an in-depth analysis of the efficacy and safety of its Digexin ingredient, which is a novel blend of Ashwagandha and okra extracts.